During the past decade, Dartmouth-Hitchcock Medical Center Hematology/Oncology conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 1 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Dartmouth-Hitchcock Medical Center Hematology/Oncology" are "Advanced BRAFV600 Wild-type Melanoma" (1 trials) and "Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Dartmouth-Hitchcock Medical Center Hematology/Oncology" in a lesser frequency.

Most popular intervention types in "Dartmouth-Hitchcock Medical Center Hematology/Oncology" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (1 trials), "Cobimetinib" (1 trials), "Pembrolizumab" (1 trials) and "picoplatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Dartmouth-Hitchcock Medical Center Hematology/Oncology" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Dartmouth-Hitchcock Medical Center Hematology/Oncology". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Dartmouth-Hitchcock Medical Center Hematology/Oncology, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Dartmouth-Hitchcock Medical Center Hematology/Oncology, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".